Immunoregulatory networks in asthma.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Immunoregulatory networks in asthma.

Clin Exp Allergy. 1998 Nov;28 Suppl 5:92-6; discussion 117-8. Unique Identifier : AIDSLINE MED/99140982
Le Gros G; Erb K; Harris N; Holloway J; McCoy K; Ronchese F; Malaghan Institute of Medical Research, Wellington, New Zealand.

Abstract: It is now well established that a subset of T-cell-derived cytokines (termed Th2 cytokines) programme the timing and characteristics of atopic airway disease including mast-cell sensitization, eosinophil and lymphocyte infiltration and recently mucus secretion. To date, attempts to devise ways to selectively limit the activities of Th2 cytokine-producing cells have been frustrated. However, the recent identification of the molecules which direct the activation and maturation of T cells has led to some successful attempts to block the activities of Th2 cells in models of atopic airway inflammation. Some of the agents with the most potential include antagonists of the T-cell costimulatory molecule CD28, local stimulators of the Thl subset of cytokines such as the BCG vaccine and potentially, antagonists of the eotaxin chemokine receptor and agonists of the T-cell costimulatory molecule CTLA-4. Not only do such agonists and antagonists represent potential new therapies, they could represent a rich hunting ground for those who aim to determine the ways in which atopic airway disease can be diagnosed and understood.

Keywords: JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL Animal Antigen-Presenting Cells/IMMUNOLOGY Antigens, CD28/IMMUNOLOGY Antigens, CD80/IMMUNOLOGY Antigens, Differentiation/IMMUNOLOGY/METABOLISM Asthma/*IMMUNOLOGY BCG Vaccine/IMMUNOLOGY Cytokines/BIOSYNTHESIS/*IMMUNOLOGY Eosinophilia/PREVENTION & CONTROL Human Hypersensitivity, Immediate/IMMUNOLOGY Mice Th2 Cells/*IMMUNOLOGY
990730
A9971187

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .